FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Nisco James
(Last) (First) (Middle)
C/O LISATA THERAPEUTICS, INC.
110 ALLEN ROAD, 2ND FLOOR
(Street)
BASKING RIDGE NJ 07920
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2024 		3. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 11,357 (1)
D
 
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) 03/23/2016 02/16/2025 Common Stock 64 580.5 D  
Stock Option (Right to Buy) 06/02/2018 06/02/2025 Common Stock 66 339 D  
Stock Option (Right to Buy) 01/25/2019 01/25/2026 Common Stock 33 94.5 D  
Stock Option (Right to Buy) 09/29/2016 09/29/2026 Common Stock 398 71.55 D  
Stock Option (Right to Buy) 01/09/2020 01/09/2027 Common Stock 39 53.1 D  
Stock Option (Right to Buy) 01/08/2021 01/08/2028 Common Stock 140 56.85 D  
Stock Option (Right to Buy) 01/14/2022 01/14/2029 Common Stock 168 74.25 D  
Stock Option (Right to Buy) 01/13/2023 01/13/2030 Common Stock 201 49.2 D  
Stock Option (Right to Buy) 01/11/2024 01/11/2031 Common Stock 466 23.85 D  
Stock Option (Right to Buy)   (2) 01/10/2032 Common Stock 1,466 13.76 D  
Stock Option (Right to Buy)   (3) 01/09/2033 Common Stock 3,000 3 D  
Stock Option (Right to Buy)   (4) 01/09/2034 Common Stock 4,000 3.08 D  
Explanation of Responses:
1. Includes (i) 732 restricted stock units granted on January 10, 2022 and vesting in four equal annual installments beginning on the grant date, (ii) 2,750 restricted stock units granted on January 9, 2023 and vesting in four equal annual installments beginning on the grant date, and (iii) 6,000 restricted stock units granted on January 9, 2024 and vesting in four equal annual installments beginning on the grant date.
2. This option was granted on January 10, 2022 and vests in four equal annual installments beginning on the grant date.
3. This option was granted on January 9, 2023 and vests in four equal annual installments beginning on the grant date.
4. This option was granted on January 9, 2024 and vests in four equal annual installments beginning on the grant date.
Remarks:
Senior Vice President, Finance and Treasury and Chief Accounting Officer Exhibit 24.1 - Power of Attorney
/s/ James Nisco 04/24/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 24.1